Bridging pathologies: Mechanistic insights into the diabetes–Alzheimer's nexus

Authors

  • Aniket Kakkar SOS School of Pharmacy (Faculty of Pharmacy), IFTM University, Moradabad, Uttar Pradesh, 244102, India; E-Mail: aniketkakkar1999@gmail.com https://orcid.org/0009-0005-5323-5035
  • Harpreet Singh School of Pharmaceutical Sciences (Faculty of Pharmacy), IFTM University, Moradabad, Uttar Pradesh, 244102, India https://orcid.org/0000-0001-5229-6569
  • Yash Jasoria School of Medical & Allied Sciences, K. R. Mangalam University, Gurugram, Haryana, India https://orcid.org/0000-0001-9091-0427
  • Arvind Kumar School of Pharmaceutical Sciences (Faculty of Pharmacy), IFTM University, Moradabad, Uttar Pradesh, 244102, India https://orcid.org/0000-0003-4754-5318
  • Shivani Chopra Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, 602105, Tamil Nadu, India https://orcid.org/0000-0002-2871-086X
  • Hitesh Chopra Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India; E-Mail: chopraontheride@gmail.com https://orcid.org/0000-0001-8867-7603
  • Arun Kumar Mishra SOS School of Pharmacy (Faculty of Pharmacy), IFTM University, Moradabad, Uttar Pradesh, 244102, India https://orcid.org/0000-0002-8569-988X

DOI:

https://doi.org/10.17179/excli2025-9165

Keywords:

Type 2 diabetes mellitus, Alzheimer’s disease, insulin resistance, oxidative stress, amyloid-beta, neurodegeneration

Abstract

Type 2 diabetes mellitus (T2DM) is increasingly recognized as a major risk factor for Alzheimer's disease (AD), with mounting evidence highlighting shared pathophysiological mechanisms. This review explores the intricate biological and molecular links between these two chronic disorders. Key overlapping pathways include impaired insulin signaling, chronic inflammation, oxidative stress, mitochondrial dysfunction, amyloid-beta (Aβ) accumulation, tau hyperphosphorylation, and the formation of advanced glycation end-products (AGEs). Disruption of insulin signaling in the brain contributes to synaptic loss and neurodegeneration, while systemic metabolic disturbances aggravate blood-brain barrier dysfunction and neurovascular damage. Emerging studies also underscore the role of antidiabetic treatments, especially newer agents targeting the gut-brain axis, in modulating AD progression. The review further examines preclinical models, clinical observations, and the development of biomarkers to improve early detection and intervention. Despite growing insights, challenges remain in translating mechanistic knowledge into effective therapies. A multidisciplinary approach integrating metabolic control and neuroprotective strategies is essential for addressing the comorbid burden of T2DM and AD.

Downloads

Published

2026-01-23

How to Cite

Kakkar, A., Singh, H., Jasoria, Y., Kumar, A., Chopra, S., Chopra, H., & Mishra, A. K. (2026). Bridging pathologies: Mechanistic insights into the diabetes–Alzheimer’s nexus. EXCLI Journal, 25, 261–289. https://doi.org/10.17179/excli2025-9165

Issue

Section

Review articles

Categories

Most read articles by the same author(s)